Multiple sclerosis (MS) is a complex disease that has growing patient numbers, counterbalanced by an increasing number of therapeutic options. In this infographic you will discover some of the drugs involved, as well as the revenues of a specific drug class (the sphingosine-1-phosphate (S1P) receptor modulator class).
To get a quick overview of the multiple sclerosis landscape, download your COMPLIMENTARY infographic now.
Get a clear perspective of the following:
- Total number of diagnosed prevalent cases of multiple sclerosis (MS) in 2016 and 2035, across the US, Japan, France, Germany, Italy, Spain and UK
- Current competitive landscape of the MS market, with timeline of US drug approvals
- Sales of the sphingosine-1-phosphate (S1P) receptor modulator class across the US, Japan, and five major EU markets ($m), 2014-23
- Key late-stage pipeline candidates, with a focus on the S1P receptor modulator siponimod, and how it compares to its predecessor, Gilenya (fingolimod)